Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China.
Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China.
复制标题
需要异基因造血干细胞移植的严重再生障碍性贫血患者的最佳供体：来自中国的大样本研究
DOI：
10.1038/s41598-018-20853-9
复制
发表时间：
2018-02-06
影响因子：
4.6
通讯作者：
Zhang X
中科院分区：
文献类型：
--
作者：
Zeng Y;Wang S;Wang J;Liu L;Su Y;Lu Z;Zhang X;Zhang Y;Zhong JF;Peng L;Liu Q;Lu Y;Gao L;Zhang X
HLA半相合造血干细胞移植（HSCT）可能是重型再生障碍性贫血（SAA）患者的一种选择。然而，到目前为止，还没有大样本的研究已经进行，以确定哪些类型的SAA患者适合HLA半相合HSCT。我们回顾性研究了189例连续SAA患者，他们在中国的7个移植中心接受了HLA相合或HLA半相合的HSCT。倾向评分匹配（PSM）在这项研究中应用，以减少潜在的混杂因素的影响。HLA半相合组和HLA相合组的5年总生存率分别为72.0%和76.5%。两组间的中位植入时间和急性GVHD/慢性GVHD发生率无显著差异。在亚组分析中，HLA半相合组中年龄大于40岁的患者的结局显著差于同组中年龄小于40岁的患者和HLA相合组中年龄大于40岁的患者。基于上述结果，我们建议，HLA半相合的相对HSCT应被视为一个有效的替代选择的患者年龄小于40岁的SAA，没有匹配的同胞供体。
HLA-haploidentical hematopoietic stem cell transplantation (HSCT) may be an option for severe aplastic anemia (SAA) patients. However, to date, no large-sample studies have been performed to determine which types of SAA patients are suitable for HLA-haploidentical HSCT. We retrospectively studied 189 consecutive patients with SAA who underwent HLA-identical or HLA-haploidentical HSCT at seven transplant centers in China. Propensity score matching (PSM) was applied in this study to reduce the influence of potential confounders. The 5-year overall survival (OS) rate was 72.0% in the HLA-haploidentical group and 76.5% in the HLA-identical group. The median time to achieve engraftment and the incidence of acute GVHD/chronic GVHD were not significantly different between the two groups. In the subgroup analysis, the outcome of patients older than 40 years in the HLA-haploidentical group was significantly poorer than that of patients younger than 40 years in the same group and that of patients older than 40 years in the HLA-identical group. Based on the above results, we suggest that HLA-haploidentical relative HSCT should be considered as a valid alternative option for patients younger than 40 years with SAA for whom no matched sibling donor is available.
登录
查看更多内容
影响因子：
4.3
作者：
Im, Ho Joon;Koh, Kyung Nam;Seo, Jong Jin
通讯作者：
Seo, Jong Jin
影响因子：
2.3
作者：
Barone, Angelica;Lucarelli, Annunziata;Saracco, Paola
通讯作者：
Saracco, Paola
DOI：
10.1182/asheducation-2011.1.76
发表时间：
2011-12-01
影响因子：
3
作者：
Guinan, Eva C.
通讯作者：
Guinan, Eva C.
影响因子：
2.3
作者：
Chen, Xing-Hua;Gao, Lei;Wang, Qing-Yu
通讯作者：
Wang, Qing-Yu
影响因子：
28.5
作者：
Gao L;Sun Y;Meng F;Han M;Huang H;Wu D;Yu L;Ren H;Huang X;Zhang X
通讯作者：
Zhang X